TWINNING FOR EXCELLENCE TO STRATEGICALLY ADVANCE RESEARCH IN CARCINOGENESIS AND CANCER

点击翻译按钮获取中文摘要

The CutCancer project aims to strengthen and increase the research and innovation capacity and excellence of the National institute of Biology (NIB) in Slovenia. This will be achieved through targeted twinning activities with three internationally renowned institutions; Swansea University from the UK, Stockholm University from Sweden and VU Medical Centre Amsterdam from the Netherlands, all of which poses specific, unique and complementary knowledge and expertise that is highly desired and needed at NIB. Together with ongoing substantial infrastructural improvements and significant research equipment upgrades, CutCancer will enable implementation of cutting-edge approaches and methodologies (including advanced in vitro 3D cell models, spatial and single-cell analyses), facilitating frontier research in the field of preclinical 3D cancer research. CutCancer will encompass the development of synergies between research institutions, fostering networking and participation in future Research and Innovation processes. CutCancer aims to go beyond the purely scientific aspects and raise the management and administrative capacity of NIB to reach top level. Twinning activities will include specific hands-on training, expert visits, webinars, workshops and summer schools, job shadowing and exchange of best practices, targeting strategically selected research and administrative areas. Results will be disseminated at international and regional conferences and targeted events for relevant stakeholders ranging from the scientific community to the health sector, professional networks, students and general public. The CutCancer´s strategic action plan will ensure that the project leads to long-term collaborations within the consortium and beyond. This will include future research projects coordinated by NIB, as well as the sharing of infrastructure and innovations brought by the newly implemented methods, approaches and strategies, targeted during the CutCancer project.